The Q1 2026 report examines the current state and outlook of the Healthcare Venture Industry in the US and Europe across Biopharma, Dx/Tools, and Medical Devices. The industry is navigating a period of transition in 2026, marked by shifting investment patterns, evolving sector priorities, and the growing influence of AI-driven innovation. While overall first-financing activity remains resilient, the market is seeing a recalibration of risk, with investors favoring quality over quantity and selectively backing companies with clear paths to value creation.

Looking ahead, the industry is poised for stability, underpinned by continued M&A activity, the strategic entry of AI and technology players, and a disciplined approach to capital deployment.

Download our report for deeper insights into the sector trends and investment drivers.

Biopharma

Biopharma first-financing investment continued a reduced investment pace in Q1 2026, with fewer mega rounds but a positive shift toward $20-50M deal sizes and higher investor risk tolerance. Preclinical assets continued to dominate early-stage deals, but larger, later-stage financings increasingly favored clinical assets and established modalities. Overall investment activity declined, and varied by therapeutic area, with growth in oncology and respiratory and declines in autoimmune and cardiovascular. M&A activity remained strong, with rising upfront values and new interest from AI-driven acquirers, signaling evolving dynamics in life sciences financing and dealmaking.

Dx/Tools

First-financing investment in Dx/Tools remained robust, matching recent highs, and overall investment maintained steady funding at $1.6B over the past three years. The focus has shifted sharply toward R&D tools, especially computational biology and manufacturing technologies, which captured most large financings. Diagnostic test investment declined sharply, while dx analytics funding stayed consistent but concentrated in a few deals. AI-Driven M&A activity is emerging, with cash-rich tech players showing increased interest in acquiring computational biology companies, signaling a potential shift in buyer dynamics.

Medical Devices

First-financing investment in medical devices posted its second-best quarter since 2023, with larger, multi-investor rounds supporting companies through key milestones. While overall investment was below 2025 peaks, it remained ahead of previous years. $50M+ deals continued at a strong pace, with a mix of early clinical stage, pivotal trial, and commercialization deals. Median capital raised and valuations are rising, prompting concerns about future M&A returns, though robust investor participation and higher upfront payments are helping to offset risks. M&A activity remains healthy, with median upfront values increasing, and IPO optionality persists despite just one IPO so far in 2026.